Proposed Actions

In fall 2021, TATFAR revised its work plan and identified 18 actions for continued collaboration through 2026. The draft work plan below should be formally adopted later in 2021.

TATFAR summarized its role and contribution to fighting AMR across the Atlantic with several fact sheets that are available for download on the Fact Sheets: Key Area Summaries webpage.

Key Area 1: Appropriate antimicrobial use in human and veterinary medicine

Key Area 1 by Action Number, Description, and Implementation Organizations
Action Number Description Implementation Organizations
1-1 Collaborate through regular exchanges of information on actions and approaches related to the consumption and appropriate use of antimicrobials in veterinary medicine.
The group will continue ongoing collaborations among TATFAR partners from the previous implementation period on approaches to promote appropriate antimicrobial use and stewardship in veterinary medicine.
CDC, CFIA, DG-SANTE, ECDC, EFSA EMA, FDA, HC, NVI, PHAC, USDA
1-2 Collaborate through regular exchanges of information on actions and approaches related to the appropriate use of antimicrobials in human medicine.
The group will exchange information on actions and approaches related to the appropriate use of antimicrobials in human medicine. The group will foster ongoing collaboration among TATFAR partners, WHO, and other non-TATFAR partners from the previous implementation period to promote appropriate antibiotic use in human medicine and accelerate the fight against AMR across the globe. The group will also discuss COVID-19’s impact on appropriate antibiotic use.
CDC, DoD, ECDC, NIPH, PHAC
1-3 Collaboration on diagnostic stewardship actions.
The group will meet on a regular basis to discuss challenges and opportunities related to integrating laboratory practices and diagnostics with antibiotic stewardship actions. The group will also consider engaging with external partners (e.g., CLSI, EUCAST) as appropriate to discuss the role of microbiology labs in diagnostic stewardship pathways and how to best improve the guidance of therapy.
CDC, DoD, ECDC, NIH, NIPH, PHAC

Key Area 2: Surveillance and prevention of AMR

Key Area by Action Number, Description, and Implementation Organizations
Action Number Description Implementation Organizations
2-1 Collaboration through regular exchanges of information on emerging resistance trends and novel strategies to detect and prevent AMR.
The group will communicate on emerging trends and AMR infection control and prevention strategies. The group will also discuss how resistance data and alerts are shared within countries and consider possibilities for improved sharing internationally via a secure network, and COVID-19 impact on control measures.
CDC, DoD, ECDC, EFSA, FDA, NIPH, NVI, PHAC, USDA
2-2 Cooperate in using mathematical modeling to accelerate AMR prevention and control efforts.
The group will work to foster transatlantic collaboration to accelerate AMR prevention efforts by increasing joint scientific evaluations using transmission modeling. This group will exchange information and discuss ongoing and future national and international actions and events related to use of transmission modeling. This work contributes towards the utilization of transmission modeling evidence to accelerate prevention efforts.
CDC, DoD, ECDC, FDA, NIPH, NVI, PHAC, USDA
2-3 Exchange information on approaches to risk analysis for foodborne AMR.
The group will continue long-standing information sharing on approaches to risk analysis for foodborne AMR. The group will share ideas and expertise on how to effectively conduct risk analysis of foodborne AMR. The group will share the latest progress on risk analysis and AMR, ways to improve current framework and models, ways to best include new types of information (e.g., fitness/virulence genetic determinants and genomic data), and how to conduct dose-response modelling of foodborne AMR.
AAFC, CDC, CFIA, DG-SANTE, ECDC, EFSA, EMA, FDA, HC, NVI, PHAC, USDA
2-4 Consultation and collaboration on prevalence surveys of healthcare-associated infections (HAIs) and antimicrobial use in hospitals and long-term care facilities, with a focus on burden estimation methods and how prevalence survey data are used at facility/local, national, and multinational levels.
The group will continue collaboration on point prevalence surveys and continue work planned in previous implementation period. The group will work to complete and publish the hospital point prevalence survey methods paper established in the last implementation period. The group will also work to continue efforts to produce publications related to long-term care survey methods and how survey data is used to address AR. The group will also continue communication around future surveys planned, considering COVID-19 impact on facilities and how address as part of assessments.
CDC, ECDC, NIPH, PHAC
2-5 Revision of the definitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pan-drug-resistant (PDR) bacteria for human infections.
The group will discuss and agree about revisions of the current definitions for MDR, XDR and PDR bacteria. The purpose of this action is to provide clear and lasting definitions and ensure they are applied consistently and correctly.
CDC, DoD, ECDC, FDA, NIPH, PHAC, USDA
2-6 Share approaches to improve AMR surveillance across the One Health spectrum (human, animal, environment).
This group will discuss ways to improve national monitoring and detection of AMR. The group will share best approaches for One Health surveillance and AMR data from humans, animals, food, and the environment as appropriate.
CDC, DoD, ECDC, EFSA, FDA, NIPH, NVI, PHAC, USDA
2-7 Consultation and collaboration on ways to explore sewage-based surveillance measures to monitor AMR.
The group will discuss and share information, best practices, and specific ways to describe, collect, and present data from wastewater monitoring to reveal the occurrence of antimicrobial resistance bacteria around the world.
AAFC, CDC, DG-ENV, DG-JRC, DG-SANTE, ECDC, EFSA, EPA, FDA, NIPH, PHAC, USDA

Key Area 3: Strategies to improve financial incentives, access, research, and development of antimicrobial drugs, diagnostics, and alternatives

Key Area 3 by Action Number, Description, and Implementation Organizations
Action Number Description Implementation Organizations
3-1 Regulatory agencies will share approaches regarding antibacterial drug development to:
  • Discuss common issues in the area of drug development and regulation
  • Consider opportunities for convergence in the requirements and regulation of antibacterial agents
BARDA, EMA, FDA, HC, NIPH, NMA
3-2 Exchange information on regulatory science research approaches to antimicrobial therapies, including traditional and alternative approaches for managing bacterial infections.
The group will exchange information on actions and approaches related to the development of alternative therapies for managing bacterial infections.
BARDA, CDC, DG-RTD, DoD, EMA, FDA, HC, NIH, NIPH
3-3 Discuss the particular challenges related to authorization of novel veterinary therapies presented as alternatives to antimicrobials.
The group will continue collaborations on discussing approaches (and challenges) related to authorization of alternatives and the initiatives already underway to promote access to market for such products while ensuring appropriate levels of quality, safety, and efficacy.
CDC, CFIA, DG-SANTE, EMA, FDA, HC, USDA
3-4 Collaborate on research to support the development of new antimicrobials, alternative approaches, and diagnostic devices, by fostering international research and product development to address challenging problems in the management of AMR.
  • Enhanced communication between TATFAR partners on cross-cutting issues related to the area
  • Enhanced collaboration among funders and with the research community
  • Focus on facilitating preclinical research/product development opportunities and enabling clinical research
BARDA, CIHR, DoD, DG-RTD, HC, HHS-OGA, NIH, NIPH
3-5 Communicate on incentives for antibiotic innovation and access.
The group will communicate, discuss, and examine incentives aiming to either (or both) stimulate antibiotic innovation or secure access to important antibiotics (including both old and new antibiotics). These incentives may also include alternative therapies.
BARDA, DG RTD, DG-SANTE, DoD, EMA, HC, HHS-OGA, NIH

Key Area 4: Cross-cutting actions to improve awareness and disseminate information from TATFAR

Key Area 4 by Action Number, Description, and Implementation Organizations
Action Number Description Implementation Organizations
4-1 Collaboration through regular exchanges of information on ways to best communicate on AMR to various audiences.
The group consists of communications subject matter experts from each respective member organization who will share communications actions and strategies on AMR. The group will also work to share important communications on AMR so that TATFAR can help amplify messages.
CDC, CFIA, DG-SANTE, DoD, ECDC, EMA, FDA, HC, HHS-OGA, NIH, NIPH, NVI, PHAC, USDA
4-2 Collaboration through regular exchanges of information on policy topics.
The group will present and share on current AMR policy and actions that may help inform policy discussions.
All TATFAR agencies, core group: CDC, CFIA, DG-SANTE, DOD, ECDC, EMA, HHS-OGA, NIPH, NVI, PHAC
4-3 Share successes and challenges related to the fight against AMR.
The group will work to develop a compendium (structured template) housed within a webpage folder (one page in a structure format for each described best practice). The resource will provide a “one-stop shop” where individuals in and outside of the TATFAR sphere can access information and resources that highlight successful practices (communication, policy, interventions, research, etc.) related to the fight against AMR.
All TATFAR agencies, core group: CFIA, DOD, ECDC, EMA, HHS-OGA, NIPH, NVI